These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Risk of thrombolytic therapy for acute ischemic stroke in patients with current malignancy. Masrur S; Abdullah AR; Smith EE; Hidalgo R; El-Ghandour A; Rordorf G; Schwamm LH J Stroke Cerebrovasc Dis; 2011; 20(2):124-30. PubMed ID: 20598579 [TBL] [Abstract][Full Text] [Related]
5. Thrombolysis for acute ischemic stroke: do patients treated out of hours have a worse outcome? Fang K; Churilov L; Weir L; Dong Q; Davis S; Yan B J Stroke Cerebrovasc Dis; 2014 Mar; 23(3):427-32. PubMed ID: 23635920 [TBL] [Abstract][Full Text] [Related]
6. Why are acute ischemic stroke patients not receiving IV tPA? Results from a national registry. Messé SR; Khatri P; Reeves MJ; Smith EE; Saver JL; Bhatt DL; Grau-Sepulveda MV; Cox M; Peterson ED; Fonarow GC; Schwamm LH Neurology; 2016 Oct; 87(15):1565-1574. PubMed ID: 27629092 [TBL] [Abstract][Full Text] [Related]
7. Early and continuous neurologic improvements after intravenous thrombolysis are strong predictors of favorable long-term outcomes in acute ischemic stroke. Yeo LL; Paliwal P; Teoh HL; Seet RC; Chan BP; Wakerley B; Liang S; Rathakrishnan R; Chong VF; Ting EY; Sharma VK J Stroke Cerebrovasc Dis; 2013 Nov; 22(8):e590-6. PubMed ID: 23954601 [TBL] [Abstract][Full Text] [Related]
8. Barriers to the use of intravenous tissue plasminogen activator for in-hospital strokes. Bunch ME; Nunziato EC; Labovitz DL J Stroke Cerebrovasc Dis; 2012 Nov; 21(8):808-11. PubMed ID: 21640608 [TBL] [Abstract][Full Text] [Related]
9. Use of tissue-type plasminogen activator before and after publication of the European Cooperative Acute Stroke Study III in Get With The Guidelines-Stroke. Messé SR; Fonarow GC; Smith EE; Kaltenbach L; Olson DM; Kasner SE; Schwamm LH Circ Cardiovasc Qual Outcomes; 2012 May; 5(3):321-6. PubMed ID: 22550132 [TBL] [Abstract][Full Text] [Related]
10. Perception Versus Actual Performance in Timely Tissue Plasminogen Activation Administration in the Management of Acute Ischemic Stroke. Lin CB; Cox M; Olson DM; Britz GW; Constable M; Fonarow GC; Schwamm L; Peterson ED; Shah BR J Am Heart Assoc; 2015 Jul; 4(7):. PubMed ID: 26201547 [TBL] [Abstract][Full Text] [Related]
11. Door-to-needle times for tissue plasminogen activator administration and clinical outcomes in acute ischemic stroke before and after a quality improvement initiative. Fonarow GC; Zhao X; Smith EE; Saver JL; Reeves MJ; Bhatt DL; Xian Y; Hernandez AF; Peterson ED; Schwamm LH JAMA; 2014 Apr 23-30; 311(16):1632-40. PubMed ID: 24756513 [TBL] [Abstract][Full Text] [Related]
12. Temporal Trends in Intravenous Thrombolysis in Acute Ischemic Stroke: Experience from a Tertiary Care Center in India. Khurana D; Das B; Kumar A; Kumar S A; Khandelwal N; Lal V; Prabhakar S J Stroke Cerebrovasc Dis; 2017 Jun; 26(6):1266-1273. PubMed ID: 28237123 [TBL] [Abstract][Full Text] [Related]
14. Direct access to a hospital offering intravenous thrombolysis therapy improves functional outcome of acute ischemic stroke patients. Kim DH; Cha JK; Park HS; Choi JH; Kang MJ; Huh JT J Clin Neurosci; 2014 Aug; 21(8):1428-32. PubMed ID: 24980628 [TBL] [Abstract][Full Text] [Related]
15. Is there a decreased risk of intracerebral hemorrhage and mortality in obese patients treated with intravenous thrombolysis in acute ischemic stroke? Hassan AE; Chaudhry SA; Jani V; Grigoryan M; Khan AA; Adil MM; Qureshi AI J Stroke Cerebrovasc Dis; 2013 May; 22(4):545-9. PubMed ID: 23453555 [TBL] [Abstract][Full Text] [Related]
17. Utilization of intravenous thrombolysis in 3-4.5 hours: analysis of the Minnesota stroke registry. Tekle WG; Chaudhry SA; Hassan AE; Peacock JM; Lakshminarayan K; Tsai A; Luepker R; Anderson DC; Qureshi AI Cerebrovasc Dis; 2012; 34(5-6):400-5. PubMed ID: 23221276 [TBL] [Abstract][Full Text] [Related]
18. Use of Strategies to Improve Door-to-Needle Times With Tissue-Type Plasminogen Activator in Acute Ischemic Stroke in Clinical Practice: Findings from Target: Stroke. Xian Y; Xu H; Lytle B; Blevins J; Peterson ED; Hernandez AF; Smith EE; Saver JL; Messé SR; Paulsen M; Suter RE; Reeves MJ; Jauch EC; Schwamm LH; Fonarow GC Circ Cardiovasc Qual Outcomes; 2017 Jan; 10(1):. PubMed ID: 28096207 [TBL] [Abstract][Full Text] [Related]
19. Role of tissue plasminogen activator in acute ischemic stroke. Hatcher MA; Starr JA Ann Pharmacother; 2011 Mar; 45(3):364-71. PubMed ID: 21386027 [TBL] [Abstract][Full Text] [Related]
20. Preclusion of ischemic stroke patients from intravenous tissue plasminogen activator treatment for mild symptoms should not be based on low National Institutes of Health Stroke Scale Scores. Wendt M; Tütüncü S; Fiebach JB; Scheitz JF; Audebert HJ; Nolte CH J Stroke Cerebrovasc Dis; 2013 May; 22(4):550-3. PubMed ID: 23433783 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]